Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors
Drug Development Research · 2025
DOI: 10.1002/ddr.70084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Alexandria M Chan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Sulfonamides, Proto-Oncogene Proteins c-bcl-2, Histone Deacetylase Inhibitors, Histone Deacetylase 6. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health..
Abstract (Originalsprache)
Motivated by the anti‐leukemic synergy between histone deacetylase (HDAC) inhibitors and the FDA‐approved BCL‐2 inhibitor venetoclax, coupled with our interests in polypharmacology, we sought to bolster the anti‐leukemic efficacy of the clinical drug by grafting HDAC1‐selective or HDAC6‐selective inhibitor motifs onto a solvent‐accessible domain of venetoclax. We discovered multiple polypharmacological agents that both retained the potent BCL‐2 inhibitory activity of venetoclax and effectively inhibited either HDAC1 or HDAC6 with excellent (up to 80‐fold) selectivities for the desired HDAC isoform. In addition, relative to parental venetoclax, two of our lead compounds, BD‐4‐213 and AMC‐4‐154 , exhibited superior activities against the acute myeloid leukemia cell line MV4;11 and an MV4;11 cell line engineered to overexpress BCL‐2. Annexin‐V assay results confirmed an on‐target mechanism of apoptosis for these novel chimeric molecules. Efforts to further boost the HDAC1 or HDAC6 binding affinities and/or selectivities proved unsuccessful due to synthetic chemistry challenges and solubility problems, which may underscore the difficulties of polypharmacology approaches involving a large inhibitor, such as venetoclax.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
- Center for Stem Cell Biology & Regenerative Medicine, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- School of Chemistry, Cardiff University Main Building, Cardiff, UK.
- Center for Stem Cell Biology & Regenerative Medicine, Departments of Pediatrics and Pharmacology, Physiology & Drug Development, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA.
ORCID-Profile: Steven Fletcher
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health.
- National Institutes of Health
Zitieren
APA
Chan, A. M., Eberly, C., Drennen, B., Goodis, C. C., Wuyts, Z., Civin, C. I., & Fletcher, S. (2025). Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors. Drug Development Research. https://doi.org/10.1002/ddr.70084
Vancouver
Chan AM, Eberly C, Drennen B, Goodis CC, Wuyts Z, Civin CI, et al. Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors. Drug Development Research. 2025. doi:10.1002/ddr.70084
BibTeX
@article{Chan2025,
author = {Chan, Alexandria M and Eberly, Christian and Drennen, Brandon and Goodis, Christopher C and Wuyts, Zoe and Civin, Curt I and Fletcher, Steven},
title = {Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70084}
}
EUVIMED